Filter Results
:
(599)
Show Results For
-
All HBS Web
(1,023)
- People (4)
- News (249)
- Research (599)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,023)
- People (4)
- News (249)
- Research (599)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Sort by
- February 2002 (Revised August 2002)
- Case
Inhale Therapeutics: Executing and Growing the Business Model
Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company.
View Details
Keywords:
Business Model;
Technological Innovation;
Health Care and Treatment;
Growth and Development Strategy;
Medical Devices and Supplies Industry
Chesbrough, Henry W., and Gillian Morris. "Inhale Therapeutics: Executing and Growing the Business Model." Harvard Business School Case 602-132, February 2002. (Revised August 2002.)
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company.
View Details
Keywords:
Mergers and Acquisitions;
Product Marketing;
Alliances;
Research and Development;
Salesforce Management;
Business Strategy;
Pharmaceutical Industry
Leonard, Dorothy A. "Manufacturing at ALZA: The Right Prescription? (C)." Harvard Business School Supplement 694-021, September 1993.
- Research Summary
Overview
By: John Beshears
In his research, Professor Beshears shows how managers can influence the behavior of customers and employees by changing the decision-making environment to call attention to a decision, to use psychological framing to shape assessments of options, or to help...
View Details
- September 2012 (Revised January 2014)
- Case
Aqua Bounty
By: Lucy White and Stephen Burn-Murdoch
Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and...
View Details
Keywords:
IPO;
Valuation;
Real Options;
Decision Tree;
Biotech;
Genetically Modified;
Salmon;
Entrepreneurship;
Finance;
Agriculture and Agribusiness Industry;
Biotechnology Industry;
North and Central America;
Europe;
South America
White, Lucy, and Stephen Burn-Murdoch. "Aqua Bounty." Harvard Business School Case 213-047, September 2012. (Revised January 2014.)
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was...
View Details
Keywords:
Public Health;
Genome Testing;
Health Care;
Ancestry;
23andMe;
Marketing;
Product Launch;
Health;
Health Care and Treatment;
Health Testing and Trials;
Genetics;
Strategy;
Health Industry;
United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (A)." Harvard Business School Case 514-086, January 2014. (Revised June 2014.)
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Laws and Statutes;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- March 1999 (Revised June 2000)
- Case
Eli Lilly: The Evista Project
By: Steven C. Wheelwright and Matt Verlinden
Describes the creation and operation of the initial two heavyweight teams for new drug development and launch. The primary focus is on one of the teams, Evista, although comparisons to the other team, Zyprexa, are included. Lilly must decide the next phase (postlaunch)...
View Details
Keywords:
Projects;
Groups and Teams;
Operations;
Management Teams;
Product Development;
Transition;
Product Design;
Business Startups;
Business Plan;
Product Launch;
Competition;
Service Operations;
Pharmaceutical Industry
Wheelwright, Steven C., and Matt Verlinden. "Eli Lilly: The Evista Project." Harvard Business School Case 699-016, March 1999. (Revised June 2000.)
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to...
View Details
Keywords:
Philanthropy;
Philanthropy Funding;
Innovation;
Funding Model;
Venture Capital;
Partners and Partnerships;
Financing and Loans;
Investment Funds;
Acquisition;
Philanthropy and Charitable Giving;
Biotechnology Industry;
Pharmaceutical Industry;
San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- March 2018
- Case
Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company
By: Rosabeth Moss Kanter and Jonathan Cohen
As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This case follows her career at the company and describes the challenges she faced as a change agent,...
View Details
Keywords:
Digital;
Engagement;
Stakeholder Engagement;
Grassroots Movement;
Organization Change And Adaptation;
Quality;
Health Care;
Health Care Industry;
Career Path;
Leading Change;
Management;
Innovation and Management;
Personal Development and Career;
Organizational Change and Adaptation;
Biotechnology Industry;
Health Industry
Kanter, Rosabeth Moss, and Jonathan Cohen. "Sandra Brown Goes Digital (A): The Promise and Perils of Social Movements in a Healthcare Company." Harvard Business School Case 318-082, March 2018.
- 12 Jul 2016
- First Look
July 12, 2016
of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic (large-molecule) drugs represent a disproportionate and growing share of all drug spending in...
View Details
Keywords:
Sean Silverthorne
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to...
View Details
Keywords:
Patents;
Product Positioning;
Competition;
Ethics;
Value;
Health Care and Treatment;
Brands and Branding;
Pharmaceutical Industry;
United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- January 2001
- Case
Merck Global Health Initiatives (B): Botswana
By: James E. Austin, Diana Barrett and James Weber
The case series focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation,...
View Details
Keywords:
Health Disorders;
Health Care and Treatment;
Private Sector;
Public Sector;
Alliances;
Problems and Challenges;
Africa;
Botswana
Austin, James E., Diana Barrett, and James Weber. "Merck Global Health Initiatives (B): Botswana." Harvard Business School Case 301-089, January 2001.
- 24 Sep 2007
- Research & Ideas
The FDA: What Will the Next 100 Years Bring?
The U.S. Food and Drug Administration, which was created by the passage of the 1906 Federal Food and Drugs Act, regulates companies and industries accounting for one-quarter of all consumer spending, roughly...
View Details
- 19 Dec 2018
- Working Paper Summaries
Find and Replace: R&D Investment Following the Erosion of Existing Products
- Research Summary
Research Interests
Research interests are focused on issues of innovation and productivity as they relate to improved outcomes in biotechnology and pharmaceutical R and D. These span topics from decision-making, organizational structure and communication, to the development of novel... View Details
- 01 Oct 2018
- Working Paper Summaries
Negative Shocks and Innovation: Evidence from Medical Device Recalls
- November 2005 (Revised November 2005)
- Case
Massachusetts General Hospital and the Enbrel Royalty
By: David S. Scharfstein and Darren R. Smart
Massachusetts General Hospital is considering selling its royalty interest in Enbrel, Amgen's blockbuster drug for the treatment of rheumatoid arthritis. In assessing whether to sell, and at what price, the hospital must determine its value to a potential buyer as well...
View Details
Keywords:
Valuation;
Price;
Investment Return;
Capital;
Value;
Revenue;
Health Care and Treatment;
Health Industry;
Biotechnology Industry;
Massachusetts
Scharfstein, David S., and Darren R. Smart. "Massachusetts General Hospital and the Enbrel Royalty." Harvard Business School Case 206-075, November 2005. (Revised November 2005.)
- 01 Aug 2023
- Cold Call Podcast
Can Business Transform Primary Health Care Across Africa?
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords:
Health Testing and Trials;
Governing Rules, Regulations, and Reforms;
Valuation;
Product Development;
Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- 2024
- Working Paper
Prozac—Controversial Blockbuster: Case Histories of Transformational Advances
By: Amar Bhidé, Srikant M. Datar and Katherine Stebbins
This case history describes the development of Prozac, a blockbuster drug that transformed
the treatment of depression – and became a cultural phenomenon in the United States. Specifically, we
chronicle the: 1) prior treatments for depression and the research that...
View Details
Keywords:
Health Care and Treatment;
Technological Innovation;
Innovation Strategy;
Technology Adoption;
Collaborative Innovation and Invention;
Innovation and Invention;
Governing Rules, Regulations, and Reforms
Bhidé, Amar, Srikant M. Datar, and Katherine Stebbins. "Prozac—Controversial Blockbuster: Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 20-135, July 2020. (Revised May 2024.)